InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast
May 18, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share […]
Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors
May 18, 2021
POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies […]
Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast
May 11, 2021
Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’
May 6, 2021
Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview
April 27, 2021
Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast
April 21, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of […]
Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer
April 19, 2021
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development Company is global developer of world-class, innovative technologies using 3D cell culture, media In the treatment of cancer, most patients receive […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market
April 16, 2021
Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models
April 9, 2021
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used […]
Predictive Oncology Inc. (NASDAQ: POAI) Taps Its Chairman to be CEO
April 5, 2021
Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and Thermogenesis During his time at Merck’s Dey L.P., Engle transitioned the company from generics to […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery
March 30, 2021
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. […]
Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance
March 29, 2021
Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research Knowledge encapsulated by Helomics AI is “gold dust,” says chief innovation officer Data, AI and biology come together at Helomics in a way […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO
March 23, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as […]
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Working on Gen 3 Fluid-to-Drain Liquid Waste Management System for Hospitals
March 19, 2021
Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025 Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal STREAMWAY Systems eliminates waste transport, disposal costs, equipment relocation and risk of exposure to potentially contaminated fluids. For every healthcare facility, particularly hospitals and surgical centers, disposal […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights
March 16, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the company’s reinforced balance sheet with net debt and equity offerings for estimated net proceeds of […]
Predictive Oncology Inc. (NASDAQ: POAI) Hits Milestone in AI Platform Development for Ovarian Cancer
March 9, 2021
Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee Project is template for future partnerships with other healthcare institutions to expand POAI’s AI-driven clinical models to other cancers The consequences of COVID-19 sent shock waves […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Development of Newly Designed System for Direct-to-Drain Fluid Waste Management
March 8, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management. According to the update the new device will see no change to its […]
Predictive Oncology Inc. (NASDAQ: POAI) Announces Fundraising Agreements to Raise Estimated $25M
March 5, 2021
POAI completes two separate fundraising initiatives: private placement, direct offering. Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively. Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow
March 4, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients
February 26, 2021
Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost […]
Predictive Oncology Inc. (NASDAQ: POAI) Receives ‘Buy’ Rating from Litchfield Hills Research in First Analyst Coverage Report
February 26, 2021
Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs Litchfield report notes several POAI strengths under “Investment Thesis” section A growing number of companies and health providers alike […]
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiaries Ink Significant Contract, Announce Sale of Media to Top Medical Centers
February 24, 2021
POAI subsidiary inks contract with significant pharmaceutical company TumorGenesis announces sale of media to research medical centers in New York City, Boston Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales worldwide by 2027 Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer
February 24, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $17.6M Private Placement
February 18, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries
February 17, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of 4,222,288 shares of POAI common stock sold at $1.75 per share, totaled $7.4 million in gross proceeds for the company, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.4M Registered Direct Offering
February 11, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock. The company expects gross proceeds of approximately […]
Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million
February 10, 2021
Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and improved vaccines One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome Predictive Oncology […]
Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine
February 8, 2021
Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform
February 8, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
February 3, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology that the company had regained compliance with the minimum bid price requirement set forth in […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report
February 2, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. […]
Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
January 28, 2021
Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options According to the American Cancer Society, an estimated 21,750 […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Strategic Contract with Large Pharmaceutical Company
January 28, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced a contract between its wholly owned subsidiary, Soluble Biotech Inc., with a large pharmaceutical company. According to the update, the work will involve using Soluble Biotech’s proprietary protein formulation technology to improve the solubility […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million
January 27, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
January 22, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering
January 19, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers
January 14, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering
January 13, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options
January 12, 2021
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering
January 8, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock at a purchase price of $0.842 […]